BioZEEN is in the business of Saving Lives. We enable customers to manufacture therapeutics that meet and exceed their Quality Benachmark by ensuring:
– Thorough understanding process
– Optimum design space analysis that encompasses process limiting permutations & combinations
– Argumentation-based design rationale
– Regulatory compliance
– Adherence to GxP & emphasis on consistency, traceability & accountability in all our deliverables
– Internal quality testing regimens that are planned & designed before execution
– Customized solutions that meet customer budget
– Respect for customer delivery timelines
Our vision, Mission, Values & Quality philosophy integrates to complete our strategic intent ensuring that all stakeholders & customers, in particular, are more confident, empowered & above all, happy with our quality services.
IAVI is a nonprofit scientific research organization that develops vaccines and antibodies for HIV, tuberculosis, emerging infectious diseases (including COVID-19), and neglected diseases. Our mission is to translate scientific discoveries into affordable, globally accessible public health solutions. Through scientific and clinical research in Africa, India, Europe, and the U.S., IAVI is pioneering the development of biomedical innovations designed for broad global access.
In Africa, IAVI focuses on research and development (R&D), research preparedness, and policy and advocacy work. Our work includes strengthening the capacity for cutting-edge basic, clinical, epidemiological, and translational research across multiple disease areas in sub-Saharan Africa (SSA) through a robust research and capacity development program. In collaboration with clinical research center (CRC) partners across Eastern, Western, and Southern Africa, IAVI is contributing to the development of next-generation vaccines for HIV and tuberculosis (TB); biomedical interventions for the prevention and control of emerging infectious diseases and other neglected tropical diseases; and antibody discovery and development for HIV prevention, treatment of snakebite, and multi-drug resistant bacteria.
By facilitating meaningful engagement with communities, advocates, and policymakers, IAVI supports the development of national and regional policies that enhance the research and regulatory environment and accelerate the translation of research to policy and practice.
We are Merck, a vibrant science and technology company. Science is at the heart of everything we do. It drives the discoveries we make and the technologies we create.
Healthcare, Life Science and Performance Materials are our core businesses. In all three sectors, we offer specialized and high-quality products.
For more than 350 years, we have been pushing the boundaries of possibility. Thanks to the constant curiosity of more than 7,200 R&D professionals, we are discovering and developing technologies that can change the landscape of entire industries. We partner with those who share our passion. Our clear goal is to achieve progress for patients, customers, and society as a whole. This is what we work for every day.
Our purpose is to solve the toughest problems in life science by collaborating with the global scientific community – and through that, we aim to accelerate access to better health for people everywhere.
From small start-up laboratories, to the largest manufacturers, we provide scientists and engineers with best-in-class lab materials, technologies and services. With the 2015 combination of Millipore and Sigma-Aldrich, we now have a broad portfolio of 300,000 products, an expanded global footprint and an industry-leading eCommerce platform.
Vaccine manufacturing can have tremendous challenges. From early-phase development to large-scale production, our process development engineers, regulatory experts and comprehensive portfolio of products and services can help manufacturers meet their process goals.
Techinvention is a Strategic advisory and Technology firm focused exclusively on the capacity building of Vaccines and Biologicals for the developing world.
Techinvention has enabled quite a few successful outcomes of capacity building projects from Concept stage to Commercial Manufacture. The Projects have encompassed all 3 models of : a) Forward Integration b) Backward Integration and c) Hybrid Concept.
We are currently working on a platform technology that will render a vaccine for COVID-19 effective and affordable along with an engineering solution that can enable setup of a manufacturing facility that’s compliant and affordable.
Using this concept, other essential recombinant vaccines can also be manufactured in the same facility on a campaign basis. This approach enables capacity building for pandemic preparedness and indigenous manufacture of specific vaccines in the EPI for the developing world, particularly Africa.
